null - FindTrial

N/A - EPITUBE-HEART

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-001965-19-FR

Enrollment

210

Registered

2021-06-23

Start date

2021-11-05

Completion date

Unknown

Last updated

2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 20.0 Level: SOC Classification code 10007541 Term: Cardiac disorders System Organ Class: 10007541 - Cardiac disorders MedDRA version: 20.0 Level: PT Classification code 10021097 Term: Hypotension System Organ Class: 10047065 - Vascular disorders

Interventions

Trade Name: NORADRENALINE Product Code: NORADRENALINE Pharmaceutical Form: Solution for infusion INN or Proposed INN: NORADRENALINE CAS Number: 51-40-1 Current Sponsor code: NORADRENALINE Other descri

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range 70 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 140

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

France

Contacts

Public ContactPERRAULT Caroline

CHU DE NANTES

bp-prom-regl@chu-nantes.fr+33243482887

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026